Recent Updates
Recently added Catalysts
CGON Positive Sentiment

SUO 2025 – TOPLINE RESULTS FROM BOND-003 COHORT P PODIUM

Friday, December 5, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CG Oncology is set to present topline results from the BOND-003 cohort at the SUO 2025 conference. This follows a series of recent positive developments, including successful trial results and participation in various investor conferences. The company continues to engage with the bladder cancer research community.
Price reaction · baseline $44.73 (2025-12-04 close) · hit pre-market · 2 other CGON headline(s) in the window, move may be shared
day 0 close · peak
-3.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • CG Oncology is actively presenting at multiple conferences.
  • The company reported positive results from a recent trial.
  • Recognition of award recipients for bladder cancer research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

by admin | Dec 5, 2025 | congress-hub-posters | 0 comments

Recent Posts

• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation

Recent Comments

Frequently Asked Questions

What is the BOND-003 cohort?

The BOND-003 cohort is part of CG Oncology's research focusing on bladder cancer treatments.

When will the results from BOND-003 be presented?

The topline results from the BOND-003 cohort will be presented at SUO 2025.

What recent achievements has CG Oncology made?

CG Oncology reported positive trial results and is actively participating in conferences.

What is the focus of the NMIBC Research Fellowship Award?

The NMIBC Research Fellowship Award supports research in non-muscle invasive bladder cancer.

ShareAdd on Google
Tags: CGON Viatris Investor Conferences Healthcare CG Oncology BOND-003 SUO 2025 bladder cancer clinical trial
Last updated: Dec 5, 2025

Biotech snapshot

Cash runway
$1028M liquidity · $15M/mo burn
~66 mo
Minimal dilution risk
Lead asset
CG0070Phase 2
Non Muscle Invasive Bladder Cancer →

Catalyst track record

+139%
best trade around CGON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for CGON.

See every catalyst's timing & PoA →